Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer

NCT03250676 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

151

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms
Breast Cancer
Estrogen-receptor Positive Breast Cancer
Cancer, Breast
Breast Cancer Female
Breast Adenocarcinoma
Estrogen Receptor Positive Tumor
ER Positive

Interventions

DRUG: H3B-6545

Sponsor

Eisai Inc.